Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Synopsys, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The investigation is focused on whether Synopsys has engaged in any unlawful activities that may have affected its stockholders [2]. - Investors who have suffered losses and are interested in discussing their legal rights are encouraged to contact the law firm [3]. Company Performance - On September 9, 2025, Synopsys reported its financial results for Q3 2025, indicating that its IP business underperformed expectations [6]. - The CEO of Synopsys expressed a more conservative outlook for Q4 while still guiding for another year of profitable growth [6]. - Following the announcement, Baird downgraded Synopsys's rating from Outperform to Neutral and reduced its price target from $670 to $535 [6]. - As a result of this news, Synopsys's stock price dropped by $216.59, or 35.84%, closing at $387.78 per share on September 10, 2025 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Confluent, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Confluent has engaged in practices that may have harmed investors, particularly in light of recent financial disclosures [1][2]. - Investors who have suffered losses and are interested in discussing their legal rights are encouraged to contact the law firm [3]. Company Background - Bragar Eagel & Squire, P.C. is a law firm recognized nationally, with a focus on representing individual and institutional investors in complex litigation [4]. - The firm operates in multiple states, including New York, South Carolina, and California, and has a track record in commercial and securities litigation [4]. Recent Financial Performance - On July 30, 2025, Confluent reported its second-quarter financial results, indicating that consumption growth was negatively impacted by optimization efforts and a shift towards self-management by an AI-native customer [6]. - Following this announcement, Confluent's stock price dropped by $8.68, or 32.86%, closing at $17.73 per share on July 31, 2025 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against MediaAlpha, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - Wolfpack Research published a report alleging that MediaAlpha is involved in consumer fraud, claiming that up to 78% of its health insurance lead-buying partners are engaged in illegal telemarketing practices [4]. - Following the report, MediaAlpha's stock price dropped by $1.92 (11.84%) to close at $14.29 on June 25, 2024 [4]. - On November 4, 2024, MediaAlpha received a letter from the FTC indicating a recommendation to file a complaint against the company for misleading advertising and false affiliations with government entities [4]. - After the FTC's announcement, MediaAlpha's stock fell by $4.46 (27.7%) to close at $11.62 on November 5, 2024 [4]. - On August 6, 2025, MediaAlpha announced a settlement with the FTC for $45 million, related to deceptive practices in collecting consumer information [4]. Next Steps - Investors who purchased MediaAlpha shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their legal rights and potential claims [3].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Align Technology, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The investigation centers on whether Align issued false or misleading statements and failed to disclose critical information to investors [2] - Align's Q2 2025 financial results, announced on July 30, 2025, missed both analyst expectations and the company's own revenue guidance, leading to a significant drop in share price by nearly 37% the following day [2] Next Steps - Investors who purchased Align shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations across state and federal courts [4]

Core Points - The Gross Law Firm has issued a notice to shareholders of PubMatic, Inc. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1] - The class period for the lawsuit is from February 27, 2025, to August 11, 2025, during which significant issues regarding ad spend and revenue were raised [1][2] - Allegations include that a major demand side platform buyer shifted clients to a new platform, leading to a reduction in revenue for PubMatic, which contradicts the company's positive statements about its business [1] Summary by Sections Allegations - The complaint alleges that PubMatic failed to disclose that a top demand side platform buyer was moving clients to a different platform, which evaluated inventory differently [1] - This shift resulted in a decrease in ad spend and revenue from this buyer, making the company's positive statements misleading [1] Class Action Details - Shareholders who purchased shares during the class period are encouraged to register for the class action, with a deadline of October 20, 2025, to seek lead plaintiff status [2] - Registration allows shareholders to receive updates on the case's progress through portfolio monitoring software [2] Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration, indicating strong demand and growth across all channels due to distribution expansion and promotional activities [2]. Group 2: Sales and Stock Performance - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply, which would negatively impact growth in Q3 2025. Following this announcement, the stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company announced disappointing quarterly consumption figures for Premier Protein RTD Shakes, leading to a stock price decline of $17.46, nearly 33%, from $53.64 to $36.18 per share [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Quanex Building Products Corporation for possible violations of federal securities laws and other unlawful business practices following disappointing financial results [1][3]. Financial Performance - On September 4, 2025, Quanex reported non-GAAP earnings per share of $0.69 for Q3 2025, which was $0.15 below consensus estimates [3]. - The company's stock price dropped by $2.73, or 13.06%, closing at $18.18 per share on September 5, 2025, in response to the earnings miss [3]. Challenges Faced - The CEO of Quanex highlighted significant operational challenges, including macroeconomic uncertainty, low consumer confidence, and issues related to the legacy Tyman window and door hardware business in Mexico [3].

Company Overview - Insperity, Inc. is a human resources and business solutions company that provides payroll, benefits, compliance, and talent management services to small and midsize businesses across the United States [3]. Allegations and Financial Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Insperity due to allegations of providing potentially misleading business information to the investing public [1]. - On August 1, 2025, Insperity disclosed a 70% year-over-year decline in earnings per share for the second quarter of 2025, attributing this decline to rising pharmacy expenses, increased benefit costs, and large insurance claims [4]. - Following the earnings announcement, Insperity's stock price fell by $14.51 per share, or 24.35%, closing at $45.07 per share on August 1, 2025 [4]. - The company also revised down its full-year earnings guidance for 2025 [4].

Core Viewpoint - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Gartner, Inc. due to allegations of misleading business information provided to investors [1][3]. Company Overview - Gartner, Inc. is a research and advisory firm that offers insights, consulting, and business tools to assist companies in making informed decisions in the technology and IT sectors [2]. Allegations and Financial Impact - On August 5, 2025, Gartner reported a slowdown in its contract growth rate, leading to a decrease in its annual revenue forecast from $6.54 billion to $6.46 billion [3]. - The management attributed this downward adjustment to cost-cutting measures implemented to mitigate potential tariff risks [3]. Stock Market Reaction - Following the announcement of the revenue forecast adjustment, Gartner's stock price fell by $92.78 per share, or 27.55%, closing at $243.93 per share on August 5, 2025 [4].

Core Viewpoint - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Lantheus Holdings, Inc. due to allegations of providing misleading business information to investors [1]. Company Overview - Lantheus Holdings, Inc. is a globally recognized company focused on the development, production, and distribution of advanced diagnostic and therapeutic products, with core expertise in oncology and cardiovascular care [3]. Alleged Wrongdoing - On August 6, 2025, Lantheus reported weaker-than-expected second-quarter results, missing earnings and revenue targets. The company cut its full-year 2025 revenue and EPS forecasts, citing tougher competition in the PSMA PET imaging market and strategic pullbacks from certain accounts [4]. - Revenue for the quarter fell to $378 million, down 4.1%, with PYLARIFY sales dropping 8.3% to $250.6 million, both below projections [4]. Market Reaction - Following the news of the disappointing results, Lantheus stock price fell by $20.76 per share, or 28.58%, closing at $51.87 per share on August 6, 2025 [5].